Consensus SUNE BIOP OTC Markets

Equities

SBFM

US8677812054

Delayed OTC Markets Other stock markets 11:15:16 2021-10-05 am EDT			5-day change	1st Jan Change
0.1175 ^USD	-1.26%		+0.34%	+657.96%

Apr. 19	Sunshine Biopharma Unit Receives Health Canada Approval for Biosimilar Product	MT
Apr. 19	Top Premarket Decliners	MT

Evolution of the average Target Price on SUNE BIOP

Price target over the last 5 years

History of analyst recommendation changes

ab5f9c4121911cca8d7064b87437.GyFi7_M5zO82W2uY9HIW7mtRj9k4XlecS-MN1AAHcvE.KlRU3bZdoNd7OSX8hxlBgR80_uxQCRrdCNY5pVlTAYVBahCbmU6IpUUQWw~3746eb2a1ed100a8000c81b8563529be

Analyst Recommendations on SUNE BIOP

Aegis Capital Initiates Sunshine Biopharma at Buy Rating With $2.60

23-08-07

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.8584 USD

Average target price

15 USD

Spread / Average Target

+1,647.44%

High Price Target

15 USD

Spread / Highest target

+1,647.44%

Low Price Target

15 USD

Spread / Lowest Target

+1,647.44%

Consensus detail

Consensus revision (last 18 months)

Analysts covering SUNE BIOP

Aegis Capital

Ratings for SUNE BIOP

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar